There is widespread hope for curbing HIV after the United States Food and Drug Administration (FDA) approved an injectable ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...